Lexin Pharmaceutical Corp. other research news

The Horsham, Penn., company received a $100,000 Phase I SBIR from the National Institutes of Allergy and Infectious Diseases to evaluate the distribution and metabolization of the company's compounds in animal models for potential use in inflammatory and coagulative diseases. ...